LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Faecal Microbiota Transplantation is a simple, effective and safe treatment in the management of C. difficile infection in daily clinical practice.

Ferre Aracil, Carlos / El Hajra Martínez, Ismael / Vera Mendoza, MaríaI Sabel / Ramos Martínez, Antonio / Muñez Rubio, Elena / Fernández-Cruz, Ana / Matallana Royo, Virginia / García-Maseda, Sarela / Sánchez Romero, Isabel / Martínez Ruiz, Rocío / Calleja Panero, José Luis

Enfermedades infecciosas y microbiologia clinica (English ed.)

2023 Volume 41, Issue 4, Page(s) 206–210

Abstract: Introduction: Faecal microbiota transplantation (FMT) is a treatment supported by wide scientific evidence and proved to be very effective in the management of Clostridioides difficile infection (CDI). The objective of this study is to analyze its ... ...

Abstract	Introduction: Faecal microbiota transplantation (FMT) is a treatment supported by wide scientific evidence and proved to be very effective in the management of Clostridioides difficile infection (CDI). The objective of this study is to analyze its effectiveness and safety in a real clinical practice setting. Methods: Retrospective, single-center and descriptive observational study in which all FMT performed between May 2016 and December 2020 were included. Technical success was defined as the successful administration of the faecal preparation in the patient's gastrointestinal tract and clinical success the disappearance of diarrhoea in the first 72 h after the procedure with no relapse within the following 8 weeks after the therapy was started. Results: 15 FMT were performed in 13 patients. Median age was 79 years (range: 40-98 years); being 60% women and 33.3% depedent persons. The indication for FMT was recurrent CDI in 84.6%. All FMTs were performed by colonoscopy and from related donors. With a first procedure, the FMT was effective in 11 of 13 patients (84.61%; 95% CI; 54.55-98.07). Time until resolution of symptoms was less than 48 h in all cases. Post-transplant follow-up was 25.66 ± 17.5 months. No significant short or long-term complications were recorded at follow-up. Conclusion: TMF is a simple, effective and safe procedure in CD infection, even in elderly patients or those with great comorbidities.
MeSH term(s)	Humans ; Female ; Aged ; Male ; Fecal Microbiota Transplantation/methods ; Clostridioides difficile ; Retrospective Studies ; Treatment Outcome ; Feces ; Clostridium Infections
Language	English
Publishing date	2023-01-19
Publishing country	Spain
Document type	Observational Study ; Journal Article
ISSN	2529-993X
ISSN (online)	2529-993X
DOI	10.1016/j.eimce.2022.01.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Eosinophilic esophagitis: an underdiagnosed cause of dysphagia and food impaction to be recognized by otolaryngologists.

Górriz Gil, C / Matallana Royo, V / Álvarez Montero, Ó / Rodríguez Valiente, A / Fernández Manzano, C / Conde García, B / García-Berrocal, J R

HNO

2018 Volume 66, Issue 7, Page(s) 534–542

Abstract: Eosinophilic esophagitis (EoE) is a recently recognised pathologic entity whose prevalence has risen significantly since first being described in 1993. Defined as a chronic, local immune-mediated disease with predominant eosinophil infiltration, it is ... ...

Title translation	Eosinophile Ösophagitis: Eine zu selten diagnostizierte Ursache von Dysphagie und Nahrungsimpaktion, die der HNO-Arzt erkennen sollte.
Abstract	Eosinophilic esophagitis (EoE) is a recently recognised pathologic entity whose prevalence has risen significantly since first being described in 1993. Defined as a chronic, local immune-mediated disease with predominant eosinophil infiltration, it is nowadays the leading cause of dysphagia and food bolus impaction in children and young adults. Genetic and environmental risk factors, and especially food antigens, trigger the disease and are in the focus of investigation as avoidance can cure three quarters of patients. The most common antigen involved is milk, followed by egg and gluten. These patients frequently come undiagnosed to the otolaryngologist with complaints of dysphagia and recurrent non-sharp food impactions, although pharyngolaryngeal reflux symptoms and other airway complaints could also be a first sign. Delayed diagnosis and treatment can produce fibrostenosis of the esophagus that greatly impairs patients' quality of life.In-office transnasal esophagoscopy with esophageal biopsy offers a unique opportunity to promptly diagnose and follow-up these patients, without causing the morbidity of repeated sedations and reducing exploration overload in gastroenterology departments. The search for food-antigen triggers, response evaluation to swallowed steroids, or proton pump inhibitors (PPIs) make multiple endoscopies and biopsies necessary every 6 to 8 weeks.There are three first-line interchangeable treatments with the same recommendation: PPIs, dietary allergen elimination and topical swallowed steroids. The choice should be discussed with the patient on an individual basis.The objective of this article is to raise awareness of this condition, update otolaryngologists with the new EoE consensus, and highlight the need for biopsy in patients with dysphagia to rule out EoE.
MeSH term(s)	Adolescent ; Child ; Child, Preschool ; Deglutition Disorders ; Eosinophilic Esophagitis/complications ; Eosinophilic Esophagitis/diagnosis ; Esophagoscopy ; Humans ; Infant ; Otolaryngologists ; Quality of Life ; Young Adult
Language	English
Publishing date	2018-06-06
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	200040-4
ISSN	1433-0458 ; 0017-6192
ISSN (online)	1433-0458
ISSN	0017-6192
DOI	10.1007/s00106-018-0516-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ul II Zs.123: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity.

Adler, Samuel N / González Lama, Yago / Matallana Royo, Virginia / Suárez Ferrer, Cristina / Schwartz, Avraham / Bar-Gil Shitrit, Ariella

Endoscopy international open

2019 Volume 7, Issue 10, Page(s) E1253–E1261

Abstract: Background and ... ...

Abstract	Background and aims
Language	English
Publishing date	2019-10-01
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2761052-4
ISSN	2196-9736 ; 2364-3722
ISSN (online)	2196-9736
ISSN	2364-3722
DOI	10.1055/a-0982-2786
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.

Calvo Moya, Marta / González Lama, Yago / Ruíz Antorán, Belén / Omella Usieto, Ignacio / El Hajra Martinez, Ismael / Santos Pérez, Elena / Menchén Viso, Belén / Matallana Royo, Virginia / González Partida, Irene / de Lucas Tellez de Meneses, Rocío / Bella Castillo, Pablo / González Rodriguez, Macarena / Vera Mendoza, María Isabel

Crohn's & colitis 360

2023 Volume 5, Issue 1, Page(s) otac051

Abstract: Background: Loss of response to anti-tumor necrosis factor drugs in patients with inflammatory bowel disease (IBD) is frequent and, in case of low drug levels, treatment intensification is recommended. In addition, in cases in which clinical response ... ...

Abstract	Background: Loss of response to anti-tumor necrosis factor drugs in patients with inflammatory bowel disease (IBD) is frequent and, in case of low drug levels, treatment intensification is recommended. In addition, in cases in which clinical response without attainment of remission (clinical, endoscopic, or radiological), intensification could be justified since higher drug levels are associated with better outcomes. For adalimumab (ADA), the standard intensification regimen is 40 mg every week (ew). Availability of ADA 80 mg prefilled pens has enabled every other week (eow) intensification. We assessed the clinical efficacy of intensification with ADA 80 mg eow. Methods: This retrospective study was conducted at a tertiary hospital in Spain. Patients with IBD receiving maintenance ADA 80 mg eow with clinical, biomarker, and drug-level assessments were included. Demographics and clinical, biological, and endoscopic evaluation of the disease before and after ADA intensification, and pharmacokinetic assessments, were collected. Results: Eighty-seven patients (72 Crohn's disease, 15 ulcerative colitis; average age 50 years) were included. Reasons for ADA intensification were: low ADA levels-<5 µg mL Conclusions: ADA intensification to 80 mg eow was safe, effective, and did not increase drug costs versus standard intensification to 40 mg ew in our experience.
Language	English
Publishing date	2023-01-10
Publishing country	England
Document type	Journal Article
ISSN	2631-827X
ISSN (online)	2631-827X
DOI	10.1093/crocol/otac051
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Conference proceedings: FAECAL MICROBIOTA TRANSPLANTATION IS A SIMPLE, EFFECTIVE AND SAFE TREATMENT IN THE MANAGEMENT OF C. DIFFICILE INFECTION IN DAILY CLINICAL PRACTICE

El Hajra Martinez, I. / Ferre Aracil, C. / Vera Mendoza, M.I. / Ramos Martínez, A. / Muñez Rubio, E. / Fernández-Cruz, A. / Matallana Royo, V. / Garcia Maseda, S. / Sanchez Romero, I. / Martinez Ruiz, R. / Blanco Rey, S. / Santos Perez, E. / Pinto Da Costa, A. / Calleja Panero, J.L.

Endoscopy

2022 Volume 54, Issue S 01

Event/congress	ESGE Days 2022, Prague, Czech Republic, 2022-04-28
Language	English
Publishing date	2022-04-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article ; Conference proceedings
ZDB-ID	80120-3
ISSN	1438-8812 ; 0013-726X
ISSN (online)	1438-8812
ISSN	0013-726X
DOI	10.1055/s-0042-1744878
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 669: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 162: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity

Adler, Samuel N. / González Lama, Yago / Matallana Royo, Virginia / Suárez Ferrer, Cristina / Schwartz, Avraham / Bar-Gil Shitrit, Ariella

Endoscopy International Open

2019 Volume 07, Issue 10, Page(s) E1253–E1261

Abstract: Background and aims: Diagnosis and monitoring of ulcerative colitis (UC) includes conventional colonoscopy. This procedure is invasive and does not exclude small-bowel Crohn’s disease (CD). Current therapeutic goals include mucosal healing which may ... ...

Abstract	Background and aims: Diagnosis and monitoring of ulcerative colitis (UC) includes conventional colonoscopy. This procedure is invasive and does not exclude small-bowel Crohn’s disease (CD). Current therapeutic goals include mucosal healing which may lead to an increased number of endoscopic procedures in many patients. The small-bowel colon capsule endoscopy (SBC-CE) system visualizes the small bowel and colon. The aim of this study was to evaluate the performance and adverse events of SBC-CE in patients with UC. Methods: This was a prospective, feasibility study involving two study sites. Patients with active UC underwent SBC-CE and colonoscopy. Kappa statistics were performed to assess the agreement between SBC-CE and colonoscopy. Adverse events (AEs) data were collected throughout and following the procedure. Results: In total, 30 consecutive patients were recruited, and 23 of those were included in the final analysis. For the primary end point, evaluation of the extent of UC disease in the colon, the percent agreement between SBC-CE and colonoscopy was moderate (56.5 %); kappa coefficient 0.42. The percent agreement between SBC-CE and colonoscopy for UC disease activity, based on Mayo endoscopic sub-score, was 95.7 %; kappa coefficient 0.86. Disease activity in the more proximal small bowel was detected in two patients with SBC-CE. No SBC-CE device-related AEs were reported. Conclusions: When comparing SBC-CE to conventional colonoscopy, there was a moderate agreement for the extent of UC disease and a very good overall agreement between the two modalities for UC disease activity.
Language	English
Publishing date	2019-10-01
Publisher	© Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2761052-4
ISSN	2196-9736 ; 2364-3722 ; 2196-9736
ISSN (online)	2196-9736
ISSN	2364-3722 ; 2196-9736
DOI	10.1055/a-0982-2786
Database	Thieme publisher's database

Order via subito

Article ; Online: Usefulness of Thiopurine Monotherapy for Crohn's Disease in the Era of Biologics: A Long-Term Single-Center Experience.

Suárez Ferrer, Cristina / González-Lama, Yago / González-Partida, Irene / Calvo Moya, Marta / Vera Mendoza, Isabel / Matallana Royo, Virginia / Arevalo Serrano, Juan / Abreu Garcia, Luis

Digestive diseases and sciences

2018 Volume 64, Issue 3, Page(s) 875–879

Abstract: Background: Thiopurines are classically used in Crohn's disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage.! ...

Abstract	Background: Thiopurines are classically used in Crohn's disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage. Aim: To evaluate the evolving use of azathioprine (AZA) monotherapy in the era of biologics. Methods: The study retrospectively analyzed clinical records of all CD patients who started treatment with AZA monotherapy at our center since 1990. Dates of starting AZA and treatment failure (TF) were collected. We defined AZA TF if it was withdrawn due to lack of efficacy or AE, or biologics were added. Results: A total of 383 patients were included: 46.5% were males and mean age was 31 (range 17-84) years. Median follow-up was 43 (range 0.2-289) months. Overall, 147 patients (38%) experienced TF. Median cumulative survival time of AZA was 126 (95% CI 105-147) months. Proportion of patients with AZA TF increased along time: 7 patients in 1990-1995 (4.7% of all TF); 8 in 1996-2000 (5.4%); 22 in 2001-2005(15%); 41 in 2006-2010 (28%); 69 in 2011-2014 (47%) (p = 0.04). 7%, 21%, 4%, 45%, and 33.3% of patients moved to biologics in each period, respectively (χ Conclusion: An important proportion of CD patients under AZA monotherapy experienced TF in our experience. Although AZA monotherapy remains useful for CD in the era of biologics, current clinical practice is shifting to anti-TNFα biologic drugs in an increasing proportion of patients.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Azathioprine/adverse effects ; Azathioprine/therapeutic use ; Biological Products/therapeutic use ; Crohn Disease/diagnosis ; Crohn Disease/drug therapy ; Crohn Disease/immunology ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/therapeutic use ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Spain ; Time Factors ; Treatment Failure ; Young Adult
Chemical Substances	Biological Products ; Gastrointestinal Agents ; Immunosuppressive Agents ; Azathioprine (MRK240IY2L)
Language	English
Publishing date	2018-12-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	304250-9
ISSN	1573-2568 ; 0163-2116
ISSN (online)	1573-2568
ISSN	0163-2116
DOI	10.1007/s10620-018-5381-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui V Zs.35: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease.

Suárez Ferrer, Cristina / Llop Herrera, Elba / Calvo Moya, Marta / Vera Mendoza, María Isabel / González Partida, Irene / González Lama, Yago / Matallana Royo, Virginia / Calleja Panero, José Luis / Abreu García, Luis

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

2016 Volume 108, Issue 2, Page(s) 79–83

Abstract: Introduction: The possibility of developing idiopathic portal hypertension has been described with thiopurine treatment despite compromises the prognosis of these patients, the fact its true prevalence is unknown.: Material and methods: A cross- ... ...

Abstract	Introduction: The possibility of developing idiopathic portal hypertension has been described with thiopurine treatment despite compromises the prognosis of these patients, the fact its true prevalence is unknown. Material and methods: A cross-sectional study was conducted in a cohort of inflammatory bowel disease (IBD) patients followed at our unit, to determine the prevalence of diagnosis of idiopathic portal hypertension (IPH) and its relationship with thiopurine treatment. Results: At the time of the analysis, 927/1,419 patients were under treatment with thiopurine drugs (65%). A total of 4 patients with IBD type Crohn's disease with idiopathic portal hypertension probably related to the thiopurine treatment were identified (incidence of 4.3 cases per 1,000). Seventy-five percent of patients started with signs or symptoms of portal hypertension. Only one patient was asymptomatic but the diagnosis of IPH because of isolated thrombocytopenia is suspected. However, note that all patients had thrombocytopenia previously. Abdominal ultrasound with fibroscan, hepatic vein catheterization and liver biopsy were performed on all of them as part of the etiology of portal hypertension. In the abdominal ultrasound, indirect portal hypertension data were observed in all patients (as splenomegaly) cirrhosis was also ruled out. The fibroscan data showed significant liver fibrosis (F2-F3). Conclusion: Idiopathic portal hypertension following thiopurine treatment in IBD patients is a rare occurrence, but it must be borne in mind in the differential diagnosis for early diagnosis, especially in patients undergoing thiopurine treatment over a long period. The presence of thrombocytopenia is often the only predictor of its development in the preclinical stage.
MeSH term(s)	Adult ; Aged ; Azathioprine/adverse effects ; Azathioprine/therapeutic use ; Cross-Sectional Studies ; Female ; Humans ; Hypertension, Portal/chemically induced ; Hypertension, Portal/diagnosis ; Hypertension, Portal/epidemiology ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/drug therapy ; Liver Cirrhosis/chemically induced ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/epidemiology ; Male ; Mercaptopurine/adverse effects ; Mercaptopurine/therapeutic use ; Middle Aged ; Pancytopenia/chemically induced ; Pancytopenia/diagnosis ; Pancytopenia/epidemiology ; Splenomegaly/chemically induced ; Splenomegaly/diagnosis ; Splenomegaly/epidemiology ; Treatment Outcome
Chemical Substances	Immunosuppressive Agents ; Mercaptopurine (E7WED276I5) ; Azathioprine (MRK240IY2L)
Language	English
Publishing date	2016-02
Publishing country	Spain
Document type	Journal Article
ZDB-ID	1070381-0
ISSN	1130-0108 ; 0212-7512
ISSN	1130-0108 ; 0212-7512
DOI	10.17235/reed.2015.3954/2015
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 199: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito